Value Hive Podcast Peter Mantas: uniQure (QURE) and Clearpoint Neuro (CLPT) Inflection
4 snips
Sep 26, 2025 Peter Mantas, a savvy biotech investor and manager at Logos LP, dives into the promising futures of uniQure and ClearPoint Neuro. He breaks down uniQure's groundbreaking 75% NFL biomarker readout, discussing its potential to transform into a multibillion-dollar franchise. Peter also outlines the commercialization hurdles and the impact of ClearPoint's delivery technology. With insights on how ClearPoint might leverage uniQure’s success and the evolving landscape of neurotherapeutics, this conversation is a must-listen for anyone keen on biotech investments.
AI Snips
Chapters
Transcript
Episode notes
Breakout Efficacy Changes Approval Odds
- uniQure's 3-year Huntington's data far exceeded expectations and likely ensures approval.
- The magnitude of NFL reduction shifts the drug from marginal to blockbuster economics with insurer coverage likely.
Efficacy Unlocks Pricing Power
- Strong efficacy both increases price justification and insurer willingness to pay.
- Hitting high efficacy moves uniQure into multi-billion dollar peak-sales territory.
Raise Capital After A Positive Readout
- Expect companies to raise capital immediately after huge positive readouts.
- Use that window to secure cash for in-house manufacturing and commercialization if desired.